Vor Biopharma (VOR) Liabilities and Shareholders Equity (2020 - 2026)

Vor Biopharma (VOR) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $506.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 363.58% year-over-year to $506.7 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 165.31% YoY), while the FY2025 annual figure was $464.1 million, up 224.81% from the prior year.
• Liabilities and Shareholders Equity rose to $506.7 million in Q1 2026 per VOR's latest filing, from $464.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $506.7 million in Q1 2026 and bottomed at $109.3 million in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $232.0 million across 5 years, with a median of $206.4 million in 2022.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 47.99% — and 2026, when it soared 363.58%.
• Vor Biopharma's Liabilities and Shareholders Equity stood at $299.4 million in 2022, then tumbled by 33.82% to $198.1 million in 2023, then retreated by 27.88% to $142.9 million in 2024, then jumped by 224.81% to $464.1 million in 2025, then grew by 9.18% to $506.7 million in 2026.
• Business Quant data shows VOR's Liabilities and Shareholders Equity at $506.7 million in Q1 2026, $464.1 million in Q4 2025, and $176.2 million in Q3 2025.